Pozen’s Migraine Agent To Be Focus Of FDA Advisory Committee Review

Naproxen/metoclopramide combination is expected to be reviewed by the Peripheral & Central Nervous System Drugs Advisory Committee May 4. Potential risk of tardive dyskinesia is expected to be discussed. FDA deemed MT-100 “not approvable” earlier this year.